Trial Profile
A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 22 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 01 May 2023 Planned primary completion date changed from 31 Mar 2023 to 30 Sep 2023.
- 05 Dec 2022 Planned primary completion date changed from 30 Sep 2022 to 31 Mar 2023.